CMS Announces Medicare GLP-1 Bridge Program for Weight Loss Medications
Similar Articles
Endoscopic Procedure Shows Promise in Preventing Weight Regain After GLP-1 Medication Use
New Enzyme Discovery Could Improve GLP-1 Drugs Like Ozempic and Wegovy
GLP-1 Medications Linked to Reduced Psychiatric Hospitalizations and Sick Leave
Preclinical Study Shows Hybrid Molecule Strategy May Improve Obesity and Diabetes Treatment
Semaglutide Shows Significant Weight Loss Benefits for Older Adults with Obesity
The Centers for Medicare & Medicaid Services (CMS) has launched a short-term pilot program to subsidize weight loss medications for eligible Medicare beneficiaries. The Medicare GLP-1 Bridge program will run from July 2026 through December 2027, offering a $50 monthly copay for specific drugs. Eligibility is based on body mass index and health status.
Facts First
- A new Medicare pilot program subsidizes weight loss drugs with a $50 monthly copay for eligible beneficiaries.
- The Medicare GLP-1 Bridge program runs from July 2026 to December 2027.
- Eligibility is based on BMI and health status, with automatic qualification for those with a BMI of 35 or higher.
- Covered medications include Wegovy, Zepbound KwikPen, and Foundayo.
- The program was extended to 18 months because not enough insurers signed on for a voluntary long-term plan.
What Happened
The Centers for Medicare & Medicaid Services (CMS) announced the Medicare GLP-1 Bridge, a short-term pilot program for weight loss medications. The program will run from July 1, 2026, through December 31, 2027. Eligible Medicare beneficiaries enrolled in a Part D plan can receive a $50 monthly copay for specific GLP-1 medications, including Wegovy (pill and injectable), Zepbound KwikPen, and Foundayo pill. CMS extended the Bridge program to 18 months because not enough insurers signed on for a voluntary long-term plan by an April deadline.
Why this Matters to You
If you are a Medicare beneficiary struggling with obesity, this program may provide access to expensive weight loss medications at a significantly reduced cost. Current cash prices for these drugs typically range from $149 to $699 per month. The $50 copay could make these treatments more affordable, though it does not count toward your Part D deductible or the annual out-of-pocket cap. Your eligibility depends on your body mass index (BMI) and health status; individuals with a BMI of 35 or higher automatically qualify, while those with a BMI of 27 or higher qualify if they have conditions such as heart disease or prediabetes. The Centers for Disease Control and Prevention (CDC) reports that approximately 40% of American adults are clinically obese.
What's Next
The program's operational details are now being established. Prescriptions must be sent via prior authorization to a central system run by CMS contractor Humana, though doctors do not need to be enrolled as Medicare providers to write prescriptions for this program. Patients already using a GLP-1 for weight loss will need their prescriber to attest that they met the clinical criteria when therapy began. The Bridge program is a pilot, and its future or a transition to a longer-term coverage model appears to depend on insurer participation and program outcomes.